Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4][11]. Core Insights - The company's Q3 2025 financial results show significant growth in vehicle sales and revenue, with a total of 174,000 new cars sold, representing a year-on-year increase of 101.8% and a quarter-on-quarter increase of 29.6%. Total revenue reached 19.45 billion yuan, up 97.3% year-on-year and 36.7% quarter-on-quarter [1]. - The gross margin for Q3 2025 was 14.5%, an increase of 6.4 percentage points year-on-year, while the net profit for the quarter was 150 million yuan, marking a turnaround from losses in the previous year [2][3]. - The company is expected to continue its strong operational performance, driven by a robust new car cycle and strong overseas market expansion. The report highlights the company's competitive advantages in product development and low manufacturing costs [2][4]. Summary by Sections Financial Performance - Q3 2025 saw the company sell 174,000 vehicles, with revenue of 19.45 billion yuan, reflecting a year-on-year growth of 101.8% and a quarter-on-quarter growth of 29.6%. The average selling price (ASP) per vehicle was 111,900 yuan, showing a slight decrease of 2.2% quarter-on-quarter but an increase of 5.4% year-on-year [1]. - The company reported a gross margin of 14.5% for Q3 2025, up 6.4 percentage points year-on-year, while the net profit was 150 million yuan, a significant improvement compared to the previous year [2][3]. Cost and Expenses - The report indicates that the sales, administrative, and R&D expense ratios for Q3 2025 were 4.9%, 3.2%, and 6.2%, respectively, with a mixed trend in expenses. Although the expense ratios showed some improvement, total expenses continued to rise, particularly in R&D [2]. Future Outlook - The company is projected to maintain strong sales momentum into Q4 2025, with expectations of continued growth in monthly sales. The report anticipates that 2026 will be a significant year for new car launches, with several models expected to perform well in the market [2][4]. - The long-term strategy of self-research and self-supply is expected to continue to yield cost advantages, enhancing the company's competitive position in the market [4].

证券研究报告 | 2025年11月18日 中国黄金国际（02099.HK） 优于大市 Q3 业绩表现亮眼，公司兼具高业绩弹性及高成长性 公司发布三季报：前三季度实现营收 9.25 亿美元，同比+99.83%；实现归母 净利润 3.41 亿美元，同比扭亏；其中，Q1/Q2/Q3 分别实现归母净利润 0.85/1.15/1.41 亿美元，Q3 环比+22.43%。公司 Q3 利润环比再次实现明显 提升，主要得益于金铜价格上涨以及甲玛矿销售折价系数提升。 核心产品产销量数据方面：公司前三季度实现黄金产量 4.02 吨，实现黄金 销量 4.21 吨。其中长山壕前三季度黄金产量约 2.12 吨，黄金销量约 2.34 吨；甲玛矿前三季度黄金产量约 1.90 吨，黄金销量约 1.87 吨。公司前三季 度实现铜产量 5.41 万吨，实现铜销量 5.33 万吨。公司 2025 年产量指引： 长山壕黄金产量指引约 2.4-2.6 吨；甲玛矿黄金产量指引约 2.15-2.3 吨， 铜产量指引约 6.3-6.7 万吨。全年的维度来看，公司金、铜产量超过指引的 可能性较高。 核心产品成本数据方面：长山壕前三季度黄金单位生产成本1639 ...

Investment Rating - The report initiates coverage with a "Buy" rating for Tongguan Gold Group, targeting a price of HKD 3.51 based on a 2026 PE of 18.5 times [3]. Core Insights - The company is benefiting from an increase in both gold prices and production volume, with a significant rise in gross profit by 143% in the first half of 2025 [4]. - The group has been included in the MSCI Global Small Cap Index, enhancing its visibility in the capital markets and attracting international investors [4]. - The strategic focus has shifted towards high-return gold mining operations, leading to a remarkable 273% increase in shareholder profit for the first half of 2025 [4]. - Expansion through mergers and acquisitions is a key strategy, with recent acquisitions aimed at enhancing production efficiency and mineral reserves [4]. Financial Forecasts - The projected net profits for the company from 2025 to 2027 are HKD 703 million, HKD 976 million, and HKD 1.207 billion, respectively, reflecting substantial growth [3]. - Revenue is expected to grow from HKD 2.145 billion in 2025 to HKD 3.280 billion in 2027, with a compound annual growth rate of approximately 17% [4]. - The earnings per share (EPS) is forecasted to increase from HKD 0.14 in 2025 to HKD 0.23 in 2027 [4]. Major Financial Data and Predictions - The company’s revenue for 2024 is estimated at HKD 1.605 billion, with a year-on-year growth of 7% [4]. - The gross profit margin is projected to improve significantly, reaching 56.46% by 2027 [22]. - The company’s PE ratio is expected to decrease from 18.78 in 2025 to 10.94 in 2027, indicating a potential undervaluation [22]. Business Operations - Tongguan Gold Group primarily engages in gold exploration and mining, with a focus on enhancing production capacity and profitability through strategic acquisitions [8]. - The company has successfully integrated several mining operations, significantly increasing its asset base and gold resources [17]. - Recent acquisitions include Huasheng Construction Investment and Rongchang Investment, aimed at expanding the company’s mineral reserves and operational capabilities [18].

Investment Rating - The report maintains a "Strong Buy" rating for Geely Automobile (00175.HK) with a target price of HKD 26.00, indicating a potential upside of 51% from the current price [1][7]. Core Insights - Geely Automobile's Q3 2025 performance shows significant growth, with revenue reaching HKD 89.2 billion, a year-on-year increase of 27% and a quarter-on-quarter increase of 15%. The net profit attributable to shareholders was HKD 3.82 billion, up by HKD 1.4 billion year-on-year and HKD 0.2 billion quarter-on-quarter [1][7]. - The company is entering a new product cycle with several competitive new models launched, including the Galaxy A7 and Galaxy M9, which are expected to drive sales growth. The sales volume in October reached 307,000 units, a year-on-year increase of 35% and a quarter-on-quarter increase of 12% [7][8]. - The report highlights the company's improved cost control, with a sales expense ratio of 6.0%, a management expense ratio of 1.5%, and a research and development expense ratio of 4.9% [7]. Financial Projections - Revenue projections for Geely Automobile are as follows: - 2024A: HKD 241.1 billion - 2025E: HKD 344.8 billion - 2026E: HKD 446.3 billion - 2027E: HKD 493.4 billion - The net profit projections are: - 2024A: HKD 16.6 billion - 2025E: HKD 17.8 billion - 2026E: HKD 24.0 billion - 2027E: HKD 27.2 billion [3][9]. Market Position and Valuation - Geely's valuation is considered low compared to its growth potential, with a projected PE ratio of 9x for 2025 and 7x for 2026. The report suggests that the current market pessimism presents a good investment opportunity [7][8]. - The report anticipates that the company will benefit from a recovery in the automotive market and an increase in overseas sales, with total sales expected to reach 3.04 million, 3.73 million, and 4.02 million units from 2025 to 2027, respectively [7][9].

证券研究报告 | 2025年11月18日 中国黄金国际（02099.HK） 优于大市 Q3 业绩表现亮眼，公司兼具高业绩弹性及高成长性 公司发布三季报：前三季度实现营收 9.25 亿美元，同比+99.83%；实现归母 净利润 3.41 亿美元，同比扭亏；其中，Q1/Q2/Q3 分别实现归母净利润 0.85/1.15/1.41 亿美元，Q3 环比+22.43%。公司 Q3 利润环比再次实现明显 提升，主要得益于金铜价格上涨以及甲玛矿销售折价系数提升。 核心产品产销量数据方面：公司前三季度实现黄金产量 4.02 吨，实现黄金 销量 4.21 吨。其中长山壕前三季度黄金产量约 2.12 吨，黄金销量约 2.34 吨；甲玛矿前三季度黄金产量约 1.90 吨，黄金销量约 1.87 吨。公司前三季 度实现铜产量 5.41 万吨，实现铜销量 5.33 万吨。公司 2025 年产量指引： 长山壕黄金产量指引约 2.4-2.6 吨；甲玛矿黄金产量指引约 2.15-2.3 吨， 铜产量指引约 6.3-6.7 万吨。全年的维度来看，公司金、铜产量超过指引的 可能性较高。 核心产品成本数据方面：长山壕前三季度黄金单位生产成本1639 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [10]. Core Insights - The company's Q3 performance is robust, with new car sales reaching 761,000 units, representing a year-on-year increase of 42.5% and a quarter-on-quarter increase of 8.1%. Total revenue for Q3 is 89.19 billion yuan, up 47.7% year-on-year and 14.7% quarter-on-quarter [1]. - The company has shown a strong ability to improve its product mix, driven by the growth in the new energy vehicle segment and a recovery in exports. However, the gross margin has slightly declined due to the increased proportion of new energy vehicles, which typically have lower margins compared to traditional fuel vehicles [2]. - The company is expected to maintain strong operational performance in Q4, with continued growth in the new energy segment and stable performance in traditional business lines [2][3]. Summary by Sections Financial Performance - In Q3, the company achieved a gross margin of 16.6%, with a year-on-year increase of 1.0 percentage points. The actual net profit attributable to the parent company for Q2 was 3.96 billion yuan, reflecting a year-on-year increase of 61.3% [1]. - For the first three quarters of 2025, the company sold 2.169 million new cars, a year-on-year increase of 45.6%, with total revenue of 239.48 billion yuan, up 26.4% year-on-year [1]. Cost and Expenses - The company’s sales, administrative, and R&D expense ratios for Q2 were 6.0%, 1.5%, and 4.9%, respectively, showing a slight decrease from the previous quarter [1]. - The report highlights that the company has maintained a stable expense structure, with expense ratios decreasing quarter-on-quarter [2]. Future Outlook - The company is expected to continue its upward trajectory, with new models like the Zeekr 9X and Galaxy M9 set to enhance the product lineup and improve profitability [2][4]. - The report projects net profits for 2025, 2026, and 2027 to be 16.6 billion, 19.68 billion, and 24 billion yuan, respectively, corresponding to PE ratios of 10.45, 8.81, and 7.24 [4].

研究报告 Research Report 18 Nov 2025 百胜中国-S Yum China Holdings (9987 HK) 2025 投资者日：创新与提效双轮驱动，目标 2030 年门店超 3 万家 2025 Investor Day: Driving Growth Through Innovation and Efficiency, Targeting Over 30000 Stores by 2030 [Table_yemei1] 观点聚焦 Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$361.00 目标价 HK$423.20 HTI ESG 4.7-4.6-4.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$129.69bn / US$16.69bn 日交易额 (3 个月均值) US$29.51mn 发行股票数目 361.42mn 自由流通股 (%) 96% 1 年股价最高最低值 HK$ ...

Investment Rating - The investment rating for the company is "Buy" [1][7] Core Views - The company reported a total revenue of HKD 8.241 billion for the fiscal year ending September 30, 2025, representing a year-on-year decrease of 2.7% [2] - The net profit attributable to the parent company was HKD 1.146 billion, showing a year-on-year increase of 0.6% [2] - The company plans to distribute an interim dividend of HKD 0.15 per share, with a payout ratio of 50.80% [2] Revenue Analysis - Domestic sales in China reached HKD 4.675 billion, down 6.0% year-on-year, but the decline has significantly narrowed compared to the previous year [3] - The company is focusing on optimizing its product mix and enhancing collaboration with distributors to improve sales performance [3] - The overseas market showed resilience, with North America generating HKD 2.161 billion in revenue, up 0.3% year-on-year, and Europe and other markets achieving HKD 0.765 billion, up 4.3% [3] Product Performance - Revenue from sofas and related products was HKD 5.550 billion, down 4.6% year-on-year, while bedding and related products saw a decline of 7.4% [4] - Other products, including smart furniture, generated HKD 0.931 billion, up 11.4% year-on-year, primarily due to growth in overseas sales [4] Profitability - The company's gross margin and net margin were 40.4% and 14.2%, respectively, reflecting increases of 0.9 percentage points and 0.5 percentage points year-on-year [5] - The improvement in profitability is attributed to effective cost control and a decrease in raw material costs [5] Investment Recommendations - The company is positioned in a large consumer market with significant growth potential, and there is optimism regarding the stability of domestic sales and the recovery of international sales [6] - Revenue forecasts for FY2026 to FY2028 are projected at HKD 17.352 billion, HKD 18.527 billion, and HKD 19.855 billion, respectively [6] - The expected earnings per share (EPS) for the same period are HKD 0.57, HKD 0.61, and HKD 0.65, with corresponding price-to-earnings (PE) ratios of 8, 8, and 7 times [7]

Investment Rating - The report maintains a rating of "Buy" for the company [3] Core Views - The company plans to issue up to 800 million shares, representing no more than 11.52% of the post-issue share capital, and will list on the Shenzhen Stock Exchange [1][6] - The company is expected to achieve positive cash flow starting in 2024, with projected free cash flow of approximately 4 billion RMB, marking the first positive cash flow since 2003 [6] - The company is focusing on cost reduction and efficiency improvements, with a significant increase in dividends and expectations for value reassessment due to the upcoming share issuance [6] Financial Data and Valuation - Revenue projections for the company show a decline from 32,495 million HKD in 2023 to 29,397 million HKD in 2025E, with a year-on-year growth rate of -14%, -7%, and -3% respectively [2][10] - Operating profit is expected to decrease from 10,473 million HKD in 2023 to 8,138 million HKD in 2025E, with corresponding year-on-year growth rates of -1%, -17%, and -7% [2][10] - Net profit is projected to decline from 4,429 million HKD in 2023 to 3,337 million HKD in 2025E, with year-on-year growth rates of -4%, -24%, and -1% [2][10] - The company’s price-to-earnings (P/E) ratio is forecasted to be 9.1x in 2025, decreasing to 7.9x by 2027 [2][10] Shareholder Information - The major shareholder is China Everbright Group Co., Ltd., holding a 43.08% stake in the company [3] Market Performance - The company's stock price has shown an absolute performance increase of 46% over the past 12 months [5]

Investment Rating - The report maintains a "Buy" rating for InnoCare Pharma [8][16] Core Insights - InnoCare Pharma's revenue for the first three quarters of 2025 increased by 60% year-on-year, reaching RMB 1.12 billion, with a net loss of RMB 64 million, which is a 77% year-on-year reduction [5][12] - The company has raised its sales target for its key product, orelabrutinib, from over 35% year-on-year growth to over 40% for 2025, following strong sales performance [6][13] - The company has a robust pipeline for both liquid tumors and autoimmune diseases, with several products in various stages of development [7][14][15] Financial Performance - For the first three quarters of 2025, orelabrutinib sales reached RMB 1.01 billion, a 46% increase year-on-year, with third-quarter sales of RMB 373 million, reflecting a 35% year-on-year and 14% quarter-on-quarter growth [5][12] - Research and development expenses for the first three quarters of 2025 were RMB 676 million, a 10% increase year-on-year, while selling expenses rose by 41% to RMB 386 million [5][12] - As of September 2025, the company had approximately RMB 7.76 billion in cash on hand [5][12] Future Outlook - The company plans to submit a New Drug Application (NDA) for orelabrutinib for the treatment of ITP in the first half of 2026 and expects to read out phase IIb data for SLE by the end of 2025 [7][14] - InnoCare Pharma anticipates submitting 5-7 IND applications targeting malignant tumors and autoimmune diseases in 2026 [15]